Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four ‘newly adopting’ countries

Hib conjugate vaccines are widely used in the industrialized world, but are just now beginning to be introduced into other countries. To identify factors facilitating rapid global introduction, we evaluated the decision-making process, mode of introduction, effectiveness, and impact on the immunizat...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 1999-11, Vol.18 (7), p.736-742
Main Authors: Wenger, Jay D, DiFabio, Jose-Luis, Landaverde, Jose Mauricio, Levine, Orin S, Gaafar, Taki
Format: Article
Language:English
Subjects:
Biological and medical sciences
Chile
Decision Making
Developing Countries
Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage
Epidemiology. Vaccinations
General aspects
Global Health
Haemophilus Infections - prevention & control
Haemophilus influenzae
Haemophilus influenzae - immunology
Haemophilus influenzae type b vaccine
Haemophilus Vaccines - administration & dosage
Humans
Immunization Programs
Immunizations
Infant
Infant, Newborn
Infectious diseases
Kuwait
Medical sciences
New vaccines
Qatar
Uruguay
Vaccines, Conjugate - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hib conjugate vaccines are widely used in the industrialized world, but are just now beginning to be introduced into other countries. To identify factors facilitating rapid global introduction, we evaluated the decision-making process, mode of introduction, effectiveness, and impact on the immunization program of Hib conjugate vaccine introduction in four non- industrialized countries through site visits and use of a standardized questionnaire. The key promoters of Hib introduction were the pediatric community and ministries of health. Local surveillance and severity data were critical in the decision to adopt Hib vaccine. Assistance with surveillance, introduction guidelines, educational material, tenders, and funding is needed to accelerate wider adoption.
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(99)00269-8